# MajesTEC-5 (NCT05695508)

> GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

No report yet. It can be ordered.

- Drugs tested: teclistamab plus daratumumab plus lenalidomide plus dexamethasone; talquetamab plus daratumumab plus lenalidomide plus dexamethasone; ramantamig (JNJ-79635322) plus daratumumab plus lenalidomide plus dexamethasone
- Indication: transplant-eligible newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05695508
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: University of Heidelberg Medical Center
- Conditions: Multiple Myeloma
- Interventions: Teclistamab (Tec); Daratumumab; Dexamethasone; Lenalidomide; Bortezomib; Talquetamab; JNJ-79635322
- Enrollment: 160
- Primary outcome: number of incidence and severity of adverse events [safety and tolerability]

## Indexed commentary on MajesTEC-5 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 51
- YouTube: 31
- Bluesky threads: 14
- Podcasts: 13
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=majestec-5-nct05695508

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05695508", "email": "<work email>"}; the inbox owner confirms by the emailed link.